ADMA Biologics Inc. [NASDAQ: ADMA] loss -2.96% on the last trading session, reaching $2.62 price per share at the time. The company report on August 10, 2022 that ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase.
Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022.
ADMA Biologics Inc. represents 196.35 million in outstanding shares, while the company has a total market value of $478.49 million with the latest information. ADMA stock price has been found in the range of $2.60 to $2.755.
If compared to the average trading volume of 2.69M shares, ADMA reached a trading volume of 2808563 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about ADMA Biologics Inc. [ADMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADMA shares is $4.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADMA stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for ADMA Biologics Inc. shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on November 11, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on November 09, 2021, representing the official price target for ADMA Biologics Inc. stock. Previously, the target price had yet another raise to $8, while Jefferies analysts kept a Buy rating on ADMA stock. On April 15, 2019, analysts increased their price target for ADMA shares from 10 to 13.
The Average True Range (ATR) for ADMA Biologics Inc. is set at 0.15, with the Price to Sales ratio for ADMA stock in the period of the last 12 months amounting to 4.35. The Price to Book ratio for the last quarter was 4.52, with the Price to Cash per share for the same quarter was set at 0.29.
Trading performance analysis for ADMA stock
ADMA Biologics Inc. [ADMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.93. With this latest performance, ADMA shares dropped by -6.09% in over the last four-week period, additionally plugging by 27.80% over the last 6 months – not to mention a rise of 133.93% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMA stock in for the last two-week period is set at 53.20, with the RSI for the last a single of trading hit 54.44, and the three-weeks RSI is set at 53.25 for ADMA Biologics Inc. [ADMA]. The present Moving Average for the last 50 days of trading for this stock 2.49, while it was recorded at 2.59 for the last single week of trading, and 1.97 for the last 200 days.
ADMA Biologics Inc. [ADMA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and ADMA Biologics Inc. [ADMA] shares currently have an operating margin of -72.41 and a Gross Margin at +0.57. ADMA Biologics Inc.’s Net Margin is presently recorded at -88.52.
Return on Equity for this stock declined to -62.46, with Return on Assets sitting at -29.61.
ADMA Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 7.90.
An analysis of insider ownership at ADMA Biologics Inc. [ADMA]
There are presently around $313 million, or 74.80% of ADMA stock, in the hands of institutional investors. The top three institutional holders of ADMA stocks are: BLACKROCK INC. with ownership of 12,590,726, which is approximately 206.539% of the company’s market cap and around 1.70% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 11,521,102 shares of the stock with an approximate value of $30.18 million in ADMA stocks shares; and BOOTHBAY FUND MANAGEMENT, LLC, currently with $27.14 million in ADMA stock with ownership of nearly -0.46% of the company’s market capitalization.
Positions in ADMA Biologics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 68 institutional holders increased their position in ADMA Biologics Inc. [NASDAQ:ADMA] by around 29,232,348 shares. Additionally, 51 investors decreased positions by around 14,611,450 shares, while 20 investors held positions by with 75,471,188 shares. The mentioned changes placed institutional holdings at 119,314,986 shares, according to the latest SEC report filing. ADMA stock had 37 new institutional investments in for a total of 4,769,984 shares, while 25 institutional investors sold positions of 2,945,022 shares during the same period.